Editing a single variant involved in AD (APOE ε4) to the protective ε2 variant is predicted to reduce the lifetime prevalence from 5%—the assumed prevalence among non-edited genomes—to 2.9% among edited genomes. The gene discussed is APOE; the disease is Alzheimer disease.